Date:2/21/2012

t, Mylan will host an investor meeting in New York City.   The presentations will be broadcast live via webcast beginning at 1 p.m. ET and are expected to conclude at 5 p.m. ET. A replay will be available for 30 days on Mylan's website after the event's conclusion. If you are unable to access the live webcast, you can participate in listen-only mode at 877.567.9753.

To access the live webcast and view the accompanying slide presentations, visit the Investor Relations section of Mylan's website, at http://investor.mylan.com, at least 15 minutes before the presentation is scheduled to begin; click on the webcast icon to register and download or install any necessary software.  

About MylanMylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

Forward Looking StatementsThis press release includes statements that constitute "forward-looking statements", including with regard to the Company's future operations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such d
'/>"/>

SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
2. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
3. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
4. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
5. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
6. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
7. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
8. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
9. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
10. Mylan Launches First Generic Version of Teveten® Tablets
11. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets